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(57) ABSTRACT 
The present invention relates to methods for protecting 
against damage caused by radiation and/or chemotherapy, 
and methods for treating bone marrow damage by reducing/ 
inhibiting Latexin expression and/or Latexin activity. The 
methods comprise administering to a subject in need thereof 
a pharmaceutical composition comprising an antagonist that 
reduces expression and/or activity of latexin, wherein 
latexin is a latexin polynucleotide variant and/or a latexin 
polypeptide variant that binds to the antagonist. 
22 Claims, 4 Drawing Sheets 
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PROTECTION AGAINST IONIZING 
RADIATION AND CHEMOTHERAPY 
TOXICITY VIA LATEXIN REGULATION 
2 
radiation passes through a cell, its high energy causes 
intracellular atoms and molecules to become excited, or 
"ionized". This ionization can break chemical bonds, pro-
duce free radicals, and damage molecules ( e.g. DNA, RNA, 
STATEMENT OF GOVERNMENT INTEREST 5 proteins, and lipids), which are vital in biological processes. 
The blood forming-organs, reproductive organs, digestive 
organs, skin, bone and teeth are primary targets of radiation. 
Among the tissues mentioned above, the blood system is 
most sensitive to radiation due to its high turnover rate. In 
This invention has been made with Government support, 
awarded by the National Center for Advancing Translational 
Sciences, National Institutes of Health, grant number 
KL2TR000116. The government has certain rights in the 
invention. 
TECHNICAL FIELD 
10 mouse model, after exposure to irradiation, blood cell num-
bers drops precipitously ( drop stage), reaching a nadir 
around day 3 (nadir stage). Subsequently, the number of 
blood cells begins to recover and reaches to a nearly normal 
The present invention relates to methods for protecting 15 
against damage caused by radiation and/or chemotherapy by 
reducing/inhibiting Latexin expression and/or Latexin activ-
ity. 
level around 30 days post irradiation (recovery stage). 
The most critical period for a subject's survival after 
radiation injury is within the first two weeks. For example, 
if mice are exposed to 6-7Gy total body irradiation, about 
the 5th or 6th day following exposure a few of the mice may 
begin to appear lethargic and start to die. Daily mortality 
BACKGROUND OF THE INVENTION 
Hematopoiesis is a complex process for producing mul-
tiple and distinct lineages of blood-borne cells throughout 
the life span of an organism. Hematopoietic stem cells 
("HSCs") represent a subset of undifferentiated cells that 
resides predominantly in the bone marrow of adult mam-
mals. HSCs, as a population, are capable of self-renewal by 
maintaining a sufficient number of HSCs within an organ-
ism's bone marrow as a reservoir of uncommitted cells that 
can be further differentiated into various types of new blood 
cells. Such newly generated blood cells emerge from the 
bone marrow and enter the circulatory system in order to 
continuously replace mature/aging circulating blood cell 
types. The ability of HSCs, as a population, to differentiate 
and to give rise to cells of multi-lineages is critical for the 
preservation of an organism. 
20 increases to a peak between the 10th and 14th day then 
gradually subsides. After the 20th day deaths are infrequent 
and the surviving mice show evidence of recovery. 
After exposure to ionizing radiation, radiation-induced 
DNA damage immediately halts cell cycle progression ( cell 
25 cycle arrest). During the period of cell cycle arrest, DNA 
repair machinery is triggered and begins to repair the 
damage. If the repair is unsuccessful, the cells are removed 
by a programmed cell death mechanism (apoptosis). HSC 
apoptosis increases after radiation exposure. At the 7th day 
30 post 6.5Gy total body irradiation, which is the time-point 
when the apoptotic rate reaches the peak, around 20% HSCs 
(Lin-Sca-1 +c-Kit+cells) undergo apoptosis. 
In some cells, the cell cycle arrest becomes permanent. 
These cells lose their proliferation capacity and become 
35 senescent. A study on human HSCs (CD133+ cells) demon-
strated that, even though these cells were successfully 
repaired, their ability to self-renew was permanently dam-
aged. An increase in pl6Ink4 a expression on HSCs also 
In order for the maintenance of steady-state hematopoi-
esis, a balance must be achieved between the rate of self-
generation (i.e., for maintaining a steady supply of HSCs) 
and the rate of differentiation (i.e., for replenishing senescent 40 
cells). Hematopoiesis occurs as a developmental continuum 
implies the induction of premature senescence in these cells. 
In some circumstances, apoptosis and senescence do not 
functionally remove all of the damaged cells. A small 
number of cells survive radiation stress with chromosome 
aberrations. These cells are dangerous due to their genomic 
instability, and have potential to result in tumorigenesis in 
45 the future. 
in that a given population of HSCs is representative of a 
heterogeneous mixture of cells, mainly composed of long-
term HSCs ("LT-HSCs") and short-term HSCs ("ST-
HSCs"). LT-HSCs are stem cells that have the capacity for 
self-renewal throughout the life span of an organism. How-
ever, ST-HSCs exhibit transient self-renewal properties for a 
limited period of time ( e.g., typically less than 8 weeks in a 
mouse) prior to undergoing full differentiation. HSCs can 
differentiate into hematopoietic progenitor cells ("HPCs") 50 
that can further differentiate into clonogenic cells, or cells of 
a single lineage. For example, the differentiation of common 
lymphoid progenitors ("CLPs") can produce T lymphocytes 
("T cells"), B lymphocytes ("B cells"), and natural killer 
cells ("NKs"). The differentiation of common myeloid pro- 55 
genitors ("CMPs") can generate blood cells of other lin-
eages, including erythrocytes, macrophages, granulocytes, 
and platelets. The maintenance of mature blood-borne cells 
in the peripheral circulation is critical for various processes, 
including oxygen delivery and immunological protection. 60 
Maintaining a stable supply of mature blood cells is 
essential for nutrient supply, pathogen defense and tumor 
surveillance in hematopoiesis. However, this homeostasis 
can be perturbed by a DNA-damaging agent such as ionizing 
radiation or chemotherapy. Ionizing radiation is a high- 65 
frequency radiation that has very high energy and the 
capacity to remove an electron from an atom. When ionizing 
Therefore, ionizing radiation induced-apoptosis is neces-
sary to balance tumorigenesis prevention and organismal 
survival. Low levels of apoptotic activity are beneficial to 
tissue regeneration and may promote the restoration of 
hematopoiesis when cells are exposed to ionizing radiation. 
SUMMARY OF THE INVENTION 
A method for protecting against hematopoietic stem cell 
(HSC) damage caused by chemotherapy and/or radiation, in 
which the subject is administered a pharmaceutical compo-
sition comprising an antagonist that reduces Latexin expres-
sion and/or Latexin activity. 
BRIEF DESCRIPTION OF DRAWINGS 
FIGS. lA and lB illustrate the Kaplan-Meier survival 
curves of mice exposed to lethal total body irradiation and 
the Kaplan-Meier survival curves of mice exposed to clini-
cally relevant total body irradiation. 
FIGS. 2A-2D illustrate the numbers of surviving LSK cell 
in one femur compared between B6 and Lxn-/- mice that 
US 10,604,756 B2 
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had been irradiated with a sub-lethal dose of irradiation (6.5 
Gy), flow cytometric analysis showing expanded LSK, LK, 
and LS cell populations at day 14 post-irradiation for both 
Lxn-/- and B6 mice, the frequencies ofhematopoietic stem 
and progenitor cells as determined by an in vitro colony 
forming cell assay, and the numbers of surviving bone 
marrow cells in one femur compared between B6 and 
Lxn-/- mice that had been irradiated with a sub-lethal dose 
of radiation. 
FIGS. 3A-3E illustrate the counts of total leukocytes, the 
counts of total neutrophils, the counts of total lymphocytes, 
the counts of total platelets, and differentiated lineage cells 
as measured by flow cytometer using lineage-specific anti-
bodies (Gr-1, Mac-1, B220 and Thy-1) of B6 and Lxn-/-
mice that had been irradiated with a sub-lethal dose of 
radiation. 
FIGS. 4A-4C illustrate the flow cytometric analysis of 
apoptotic cells on day 14 post-irradiation using Annexin-V 
and DNA dye staining, analysis of apoptotic rate dynamics 
(over 56 days post-irradiation) in LSK population, and the 
apoptotic frequency of LSK, LK, LS and LIN- sub-popu-
lations in day 14 post-irradiation ofB6 and Lxn-/- mice that 
had been irradiated with a sub-lethal dose of radiation. 
DETAILED DESCRIPTION OF THE 
INVENTION 
It has been surprisingly discovered that down-regulating 
Latexin (Lxn) protects hematopoietic progenitor and stem 
cells from damage caused by ionizing radiation and/or 
chemotherapy and accelerates hematopoietic and immuno-
logic recovery. 
It has also been surprisingly discovered that down-regu-
lating Lxn suppresses radiation-induced apoptosis in 
hematopoietic progenitor and stem cells. 
It has also been surprisingly discovered that treating a 
subject that could potentially be exposed to radiation (e.g. a 
subject scheduled for radiation treatment, or a subject acci-
dentally exposed to environmental radiation) with a phar-
maceutical composition comprising an antagonist that 
reduces Lxn expression and/or Lxn activity protects 
hematopoietic progenitor and stem cells from potential 
damage that could be caused by the radiation and accelerates 
hematopoietic and immunologic recovery. The subject may 
be a mammal, e.g., a primate, e.g., a human, a cow, pig, dog, 
cat, rat or mouse. 
These discoveries provide methods for protecting HSCs 
in subjects, e.g., human patients, undergoing radiation 
therapy, chemotherapy, or subjects that have been or could 
be exposed to radiation ( environmental, medical, or other-
wise). 
Definitions 
As used throughout the specification and the appended 
claims, the terms listed below have the following meanings, 
wherein "a" means one or more: 
4 
HSCs include non-embryonic stem cells isolated from post-
natal animals, which are known as adult stem cells. HSCs 
are isolated from the bone marrows of mammals that are 
capable of differentiating into ectodermal lineages of blood 
5 cells. HSCs include undifferentiated stem cells that exhibit 
a distinct profile of cell surface markers, including the 
following combination of markers: Thy-1 10 Sca-1 + Lineage-
c-kit+; or CD15o+CD48- Sca-1+ Lineage- c-kit+; or Thy-1 10 
CD150+ CD48- Sca-1+ Lineage- c-kit+ (Kiel et al. Cell, 
10 Vol. 121, p. 1109-1121 (2005)). HSCs that express the 
combination of human counterparts for these markers are 
preferably contemplated. The following references are 
herein incorporated by reference in their entirety: Cheshier 
15 
et al. PNAS Vol. 96, p. 3120-3125 (1999); Eckfeldt et al. 
Nature, Vol. 6, p. 726-737 (2005); Wright et al. Science Vol. 
94, p. 1933-1936 (2001); and Preston et al. J. Clin. Pathol. 
Vol. 56, p. 86-96 (2003). 
The term "Latexin" ("Lxn") refers to the Lxn gene, 
20 isoforms/variants of the Lxn gene, and gene products 
derived from the Lxn gene, including messenger RNA and 
protein. The sense-strand of a human Latexin cDNA is 
provided as SEQ ID NO: 1. A human Latexin protein 
sequence is provided as SEQ ID NO:2. Latexin isoforms/ 
25 variants include genes containing exon sequences having at 
least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 
98%, or 99% sequence similarity to SEQ ID NO: 1; genes 
containing ex on sequences having at least about 70%, 75%, 
80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence 
30 identity to SEQ ID NO: 1; those sequences encoded by genes 
containing exon sequences having at least about 70%, 75%, 
80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence 
similarity to SEQ ID NO: 1; those sequences encoded by 
genes containing exon sequences having at least about 70%, 
35 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% 
sequence identity to SEQ ID NO: 1; those sequences having 
at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 
98%, or 99% sequence similarity to SEQ ID NO:2; and 
those sequences having at least about 70%, 75%, 80%, 85%, 
40 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to 
SEQ ID NO:2. Latexin isoforms/variants include mamma-
lian homologs listed in Tables 1-3. Variants useful in the 
methods of the present invention includes variants of SEQ 
ID NO: 1 and/or SEQ ID NO:2 as described above, and in 
45 some embodiments variants useful in the methods of the 
present invention include the variants of SEQ ID NO: 1 or 
SEQ ID NO:2 excluding the carboxypeptidase inhibitor 
(CARIN) described in U.S. Pat. No. 5,998,373. 
The term "antagonist" refers to any compound or com-
50 position that can inhibit the expression and/or the activity of 
Latexin and Latexin isoforms, including sequence-specific 
polynucleotides that can interfere with the transcription of 
endogenous Latexin gene; sequence-specific polynucle-
otides that can interfere with the translation of Latexin 
55 mRNA transcripts ( e.g., siRNAs, ribozymes ); sequence-
specific polypeptides that can interfere with the protein 
stability ofLatexin, the enzymatic activity ofLatexin, and/or 
the binding activity of Latexin with respect to substrates 
The terms "hematopoietic stem cells" ("HSCs") refer to a 
heterogeneous mixture of undifferentiated primitive stem 
cells, mainly composed of long-term HSCs ("LT-HSCs") 
and short-term HSCs ("ST-HSCs"). LT-HSCs are undiffer-
entiated stem cells that have the capacity for self-renewal 60 
throughout the life span of an organism. ST-HSCs are 
undifferentiated stem cells that have the capacity for self-
renewal for a limited time prior to full differentiation into a 
specific lineage. For example, HSCs can differentiate into 
hematopoietic progenitor cells ("HPCs") that can further 65 
differentiate into clonogenic cells, or cells of a single lin-
eage, that represent a subset of a hematopoietic lineage. 
and/or regulatory proteins; and small molecule compounds 
that can interfere with the protein stability of Latexin, the 
enzymatic activity of Latexin, and/or the binding activity of 
Latexin. An effective antagonist can promote HSC prolif-
eration by at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 
60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%. An 
effective antagonist can suppress HSC apoptosis by at least 
25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 
75%, 80%, 85%, 90%, 95%, or 100%. 
US 10,604,756 B2 
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Protection of Radiation and/or Chemotherapy Damage 
Described herein are methods for protecting against dam-
age caused by radiation and/or chemotherapy, in which the 
method comprises administering to a subject in need thereof 
a pharmaceutical composition comprising an antagonist that 5 
reduces Latexin expression and/or Latexin activity. 
The present methods enable persons of skill in the art to 
decrease apoptotic frequency of HSCs and/or to promote 
HSC proliferation within the bone marrow of patients 
affected by genotoxic stress, such as radiation or chemo- 10 
therapy. 
Subjects in need thereof include manmialian subjects that 
have either already been exposed to radiation at levels 
sufficient to damage HSCs, and/or chemotherapy, or have 
not yet been exposed to such levels of radiation, and/or 15 
chemotherapy. The subject in need thereof preferably has 
normal levels of latexin expression in their bone marrow. In 
one embodiment the subject in need thereof has a solid 
tumor and is either already receiving chemotherapy and/or 
radiation therapy, or is scheduled to start chemotherapy 20 
and/or radiation therapy. In another embodiment, the subject 
in need thereof is likely to be exposed to radiation therapy 
and/or chemotherapy or a chemotherapeutic agent. The 
present methods include providing a pharmaceutical com-
position prior to exposure to radiation and/or chemotherapy/ 25 
chemotherapeutic agent in order to protect the HSCs from 
damage caused by the radiation and/or chemotherapy/che-
motherapeutic agent. 
Protection against damage to HSCs is indicated, e.g., by 
an increase in the overall survival of the subject, by pro- 30 
tecting the cells from DNA damage caused by the chemo-
therapy and/or radiation, by a decrease in the frequency of 
HSC apoptosis, and/or by an increase in HSC proliferation 
within the bone marrow of the subject. 
The pharmaceutical composition useful in the methods 35 
described herein comprises a therapeutically effective 
amount of the latexin antagonist. The pharmaceutical com-
position may further comprise a pharmaceutical excipient 
known by persons skilled in the art. Pharmaceutical formu-
lations for effective delivery of pharmaceutical composition 40 
will vary depending on the Latexin antagonist and mode of 
administration. Suitable pharmaceutical excipients and car-
riers are known by persons skilled in the art (Remington's 
Pharmaceutical Sciences (1989), which is incorporated in 
entirety). Pharmaceutical compositions and formulations 45 
can be administered by various methods, including by 
injection, oral administration, inhalation, transdermal appli-
cation, or rectal administration. For oral administration, 
suitable formulations containing a pharmaceutical com-
pound and pharmaceutically-compatible carriers can be 50 
delivered in various forms, such as tablets or capsules, liquid 
solutions, suspensions, emulsions, and the like. For inhala-
tion, suitable formulations containing a pharmaceutical 
compound and pharmaceutically-compatible carriers can be 
delivered as aerosol formulations that can be placed into 55 
pressurized propellants, such as dichlorodifluoromethane, 
propane, nitrogen, and the like. For parenteral administra-
tion, suitable formulations containing a pharmaceutical 
compound and pharmaceutically-compatible carriers can be 
delivered by intra-articular, intra-venous, intramuscular, 60 
intra-dermal, intra-peritoneal, and sub-cutaneous routes. 
Pharmaceutical compositions suitable for use include 
compositions containing a latexin antagonist in a therapeu-
tically-effective amount to achieve its intended purpose. 
More specifically, a therapeutically-effective amount of the 65 
latexin antagonist means an amount effective to protect 
HSCs from the damage caused by exposure to ionizing 
6 
radiation and/or chemotherapy. Determination of the effec-
tive amounts is well within the capability of persons skilled 
in the art. A dose can be formulated in animal models to 
achieve a circulating concentration range that includes IC50 
value, defined as a dose in which 50% of cells of a culture 
show an effect due to the test compound. Such information 
can be used to more accurately determine useful doses in 
human subjects. 
Toxicity and therapeutic efficacy of latexin antagonists 
can be determined by standard pharmaceutical procedures 
utilizing cell cultures or experimental animals in order to 
determine a LD50 value, the dose determined to be lethal to 
50% of the exposed population, and to determine a ED50 
value, the dose determined to be therapeutically effective in 
50% of the exposed population. A dose ratio between toxic 
effect and therapeutic effect is referred to as the "therapeutic 
index," or it can be expressed as the ratio of the LD50 value 
over the ED50 value. Compounds that exhibit high thera-
peutic indices are preferred. The data obtained from cell 
culture assays and animal studies can be used in formulating 
a range of effective dosage for human usage. Optimal dosage 
range includes a ED50 dose with minimal toxicity, although 
the dosage may vary within this range depending on a given 
pharmaceutical formulation and route of administration. 
Dosage administered to a subject should be adjusted accord-
ing to the age of the subject, the weight of the subject, the 
manner of administration, and other circumstances unique to 
each subject. 
Exemplary Antagonists that Inhibit the Expression and/or 
Activity of Latexin and Latexin IsoformsNariants 
A HSC population obtained from a donor can be induced 
to proliferate ex vivo under in vitro conditions, or an 
endogenous HSC population within a patient can be induced 
to proliferate in situ by exposing the HSC population of 
interest to various antagonists that can inhibit Latexin gene 
expression and/or Latexin activity. 
Suitable antagonists that can inhibit the expression and/or 
the activity of Latexin and Latexin variants include 
sequence-specific polynucleotides that can interfere with the 
transcription of endogenous Latexin gene; sequence-specific 
polynucleotides that can interfere with the translation of 
Latexin mRNA transcripts (e.g., siRNAs, ribozymes); 
sequence-specific polypeptides that can interfere with (a) the 
protein stability of Latexin, (b) the enzymatic activity of 
Latexin, and/or ( c) the binding activity of Latexin with 
respect to substrates and/or regulatory proteins; antibodies 
that exhibit specificity for Latexin; and small molecule 
compounds that can interfere with the protein stability of 
Latexin, the enzymatic activity of Latexin, and/or the bind-
ing activity of Latexin. An effective antagonist can promote 
HSC proliferation by at least 25%, 30%, 35%, 40%, 45%, 
50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%,or 
100%, preferably by 25% to 75%, more preferably 25% to 
50%. 
Sequence-Specific Compounds 
In one embodiment, various interfering RNAs (RNAi) 
that are complementary to human Latexin mRNA and mam-
malian orthologs can be employed by persons skilled in the 
art to protect HSCs from the damage caused by ionizing 
radiation and/or chemotherapy. By introducing such RNAi 
compounds to a recipient subject that has been or will be 
exposed to ionizing radiation therapy, ionizing radiation of 
levels sufficient to damage HSCs, and/or chemotherapy, the 
silencing or inactivation effect of RNAi compounds on 
Latexin gene/gene products within the HSCs can protect 
HSCs from the damage caused by ionizing radiation and/or 
chemotherapy. 
US 10,604,756 B2 
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Because introduction of double-stranded RNA 
("d5RNA") that are longer than 30 nucleotides into mam-
malian cells induces a sequence-nonspecific interferon 
response, alternative methods for delivery of interfering 
RNA molecules ("RNAi") may be suitable. For example, 
most common form ofRNAi molecules are short-interfering 
RNAs ("siRNAs") of21-23 base-pairs that are chemically or 
enzymatically synthesized, which can be introduced into 
mammalian host cells by various methods, including trans-
fections. However, unlike fungi, plants, and worms that can 
replicate siRNAs in vivo, transfection of siRNA produces 
only transient gene-silencing effect in mammalian cells. As 
an alternative, DNA vectors encoding precursor-like forms 
of siRNAs may be used for stable production of siRNAs in 
vivo in various cells, including mammalian cells. 
In another embodiment, the compounds that protect HSCs 
from the damage caused by ionizing radiation and/or che-
motherapy comprise an oligonucleotide that can interact 
with endogenous messenger RNA encoded by Latexin gene 
or by Latexin isoforms having at least about 70%, 75%, 
80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence 
similarity to SEQ ID NO: 1 (i.e., a sense-strand of human 
Latexin cDNA). Such RNA oligonucleotide compounds can 
be single-stranded or double-stranded. Suitable lengths of 
RNA oligonucleotides include molecules containing 15-20 
nucleotides, 20-30 nucleotides, 30-50 nucleotides, 50-75 
nucleotides, 75-100 nucleotides, 100-150 nucleotides, 150-
200 nucleotides, and 200-300 nucleotides. In another 
embodiment, the antagonist of latexin that can protect HSCs 
from the damage caused by ionizing radiation and/or che-
motherapy include an anti-sense strand that can hybridize to 
an endogenously produced messenger RNA, and that can 
inhibit the translation of the messenger RNA. 
Selection of effective siRNAs useful in the methods of 
this invention is based on certain known rules governing 
optimal selection of siRNAs. For example, siRNAs contain-
ing sequence motifs, such as AAN19TT, NAN19NN, 
NARN 1 7 YNN, and NANN 17 YNN, are effective, in which N 
is any nucleotide, R is a purine, and Y is a pyrimidine. In 
addition, regions of complementary DNA should have non-
repetitive sequences, and should avoid intronic sequences. 
Suitable siRNAs contain approximately 30-70% GC con-
tent, contain even representation of all nucleotides on the 
antisense strand, and do not contain stretches of single 
nucleotide, especially stretches of Gs. Designing suitable 
siRNA molecules is within the scope of persons skilled in 
the art. The following references are herein incorporated by 
reference in their entirety: Henschel et al. Nucleic Acids 
Research, Vol. 32: 113-120 (2004); Naito et al. Nucleic 
Acids Research, Vol. 32: 124-129 (2004); Dorsett et al. Vol. 
3: 318-329 (2004); and Brummelkamp et al. Nature 
Reviews, Vol. 3: 781-789 (2003); Pusch et al. Nucleic Acid 
Research, 31: 6444-6449 (2003); and Chiu et al. RNA 9: 
1034-1048 (2003). 
Although any region of mRNA can be theoretically tar-
geted, certain sequences that are known binding sites for 
mRNA-binding proteins should be avoided, including 
untranslated regions, such as the "5'UTR" and "3'UTR," 
start-codons, and exon-exon boundaries. For some mRNA 
targets, siRNA-directed silencing may be more effective if 
the mRNA targeted siRNA sequence is selected at least 
50-100 nucleotides downstream of a start codon, and pref-
erably directed towards the 3' end of a target mRNA. In 
addition, the conformation of an mRNA recognition site 
within an mRNA target is preferably RNAse-H-sensitive, 
and preferably not within a highly-structured RNA region. 
These guidelines are generally applicable since the choice of 
8 
a siRNA depends on the target mRNA sequence, and persons 
skilled in the art would only need to synthesize several 
siRNAs to validate the efficiency of each. The specificity of 
a siRNA for a single gene can be ascertained by performing 
5 a multiple genome-sequence alignment; such as a BLAST 
search of the selected sequence against sequence databases, 
including "Unigene" libraries associated with National Cen-
ter for Biotechnology Information (NCBI). Potential off-
target silencing by siRNA may be minimized by choosing a 
10 siRNA sequence with maximum sequence divergence from 
a list of genes with partial-sequence identity to the intended 
mRNA target. General principles for siRNA selection are 
taught by the following two review articles, which are 
incorporated by reference (Dorsett and Tuschl, Nature 
15 Reviews Vol. 3: 318-329, (2004); Dykxhoorn et al. Nature 
Reviews Vol. 4: 457-467 (2003)). 
Various expression vectors can be constructed to enable 
stable production of siRNA-like molecules in vivo. For 
example, RNA-pol II promoters may be operably-linked to 
20 a hairpin precursor of a siRNA sequence of interest. RNA-
pol II promoters represent a broad range of promoters that 
enable substantial control over parameters governing RNA 
expression, such as inducible, constitutive, tissue-specific, 
or developmentally-regulated RNA expression. Alterna-
25 tively, RNA-pol III promoters may be used to produce short 
RNA species that do not activate the interferon pathway. 
Suitable RNA-pol III promoters include class III promoters 
that lack essential transcriptional elements downstream of a 
transcription initiation site, such as U6 and Hl promoters, 
30 which may be operably-linked to a siRNAencoding 
sequence. 
Long-hairpin RNAs, imperfect shRNAs, miRNAs, and 
siRNAs, to be used in the present methods can be designed 
as follows. For example, a sub-sequence of a messenger 
35 RNA encoded by Latexin gene or by Latexin isoforms 
having at least about 70%, 75%, 80%, 85%, 90%, 95%, 
96%, 97%, 98%, or 99% sequence similarity to SEQ ID 
NO:1 (i.e., a sense-strand of human Latexin cDNA), can be 
targeted. For example, an anti-sense strand of shRNA can be 
40 designed by selecting a sub-sequence portion of a RNA 
sequence complementary to endogenous Latexin messenger 
RNA and Latexin isoforms having at least about 70% 
sequence similarity to SEQ ID NO: 1. 
For designing siRNA, the composition and size of the 
45 loop and length of the stem of a hairpin duplex should be 
considered. Suitable stem lengths for efficient silencing 
include a broad range, including stem lengths of 19-29 
nucleotides. Suitable loop lengths for efficient silencing 
include a broad range, including loop lengths of 4-23 
50 nucleotides. In certain context, hairpin structures with 
duplexed regions that are longer than 21 nucleotides may 
promote effective siRNA-directed silencing, regardless of 
loop sequence and length. 
Various gene-delivery vectors that are practiced by per-
55 sons skilled in the art can be used to introduce the present 
expression vectors. Examples of viral vectors that may be 
used to infect HSC cells include: improved adenoviral 
vectors (Reynold et al. Nature Biotechnology 19: 838-842 
(2001)); gene-deleted adenovirus-transposon vectors (Yant 
60 et al. Nature Biotechnology 20: 999-1005 (2002)); recom-
binant adenoviruses (Bilang-Bleuel et al. Proc. Natl. Acad. 
Sci. U.S.A. 94: 8818-8823 (1997)); the Moloney-murine-
leukemia-virus ("Mo-MuL V") based retroviral vectors 
(Auten et al., Human Gene Therapy 10: 1389-99 (2003)); 
65 and poliovirus-replicon-based vectors (Bledsoe et al., 
Nature Biotechnology 18: 964-969 (2000)). Examples of 
other suitable viral vectors include: herpes virus, mumps 
US 10,604,756 B2 
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In another embodiment, suitable antagonists include small 
molecules that can bind polypeptides having at least about 
70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% 
sequence similarity to SEQ ID NO:2, that can inhibit the 
virus, Sindbis virus, vaccinia virus, such as the canary pox 
virus, and lentivirus. The usage of viral vectors is well 
known by persons skilled in the art, and for gene therapy 
uses, viral infection is preferred generally. The following 
references are incorporated by reference in their entirety: 
Robbins and Ghizzani, Mo!. Med. Today 1:410-417 (1995); 
Robin et al. Stem Cells 20:514-521 (2002); Chen et al., 
Immunity 19:525-533 (2003); North et al. Immunity 16: 
661-672 (2002); Zhou et al., Nature Medicine 7: 1028-1034 
(2001); Ivanova et al. 298: 601-604 (2002); and Santos et al. 
Science 298: 597-600 (2002). 
5 activity of the bound polypeptide, and that can promote the 
proliferation of HSCs and/or suppress the apoptosis of 
HSCs. In addition, small molecules that can interact with 
genomic DNA containing exons having at least about 70%, 
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% 
In one embodiment, various oligodeoxyribonucleic acid 
(ODN) molecules that are complementary to endogenous 
messenger RNA encoded by Latexin gene or by Latexin 
isoforms having at least about 70%, 75%, 80%, 85%, 90%, 
95%, 96%, 97%, 98%, or 99% sequence similarity to SEQ 
ID NO: 1 (i.e., a sense-strand of human Latexin cDNA), can 
10 sequence similarity to SEQ ID NO:1 (i.e., a sense-strand of 
human Latexin cDNA) can be employed. In addition, com-
pounds that can interact with RNA transcripts encoded by a 
gene, in which the exon sequences have at least about 70%, 
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% 
be employed by persons skilled in the art to protect HSCs. 
15 sequence similarity to SEQ ID NO:1 (i.e., a sense-strand of 
human Latexin cDNA) can be employed. Various com-
pounds that can inhibit the expression and/or activity of 
Latexin or Latexin isoforms can be either naturally-occur-
ring or synthetically-produced. Large combinatorial libraries By introducing such oligodeoxyribonucleic acid (ODN) 
molecules to a recipient subject that has been or will be 
exposed to ionizing radiation and/or chemotherapy, the 
silencing or inactivation effect of RNAi compounds on 
Latexin gene/gene products within the HSCs can protect 
HSCs from the damage caused by ionizing radiation and/or 
chemotherapy. Suitable oligodeoxyribonucleic acid mo!- 25 
ecules ("ODN s") are short polynucleotides of approximately 
20 of chemical/biological compounds can be generated by 
various chemical and biological synthesis methods known in 
the art. Such combinatorial chemical libraries include: small 
organic molecule libraries (benzodiazepines, Baum C&EN, 
20 nucleotides in length that can hybridize with pre-mRNA 
and mRNA to form RNA-DNA duplexes, which are 
degraded by ribonuclease H ("RNase H"). Such ODNs can 
be chemically modified to prevent the action of RNase H, to 30 
inhibit translation of mRNA by steric hindrance, to inhibit 
splicing of pre-mRNAs, and to inhibit transcription by the 
formation of triple helices. Kurreck, J. et al., Eur. J. Bio-
chem., 270:1628-1644 (2003); Baker et al., J. Biol. Chem., 
272:11994-2000 (1997); Lu, Q. L. et al, Nature Med., 35 
9:1009-1014 (2003); and Uil, et al., Nucleic Acids Res., 
31:6064-6078 (2003) are incorporated by reference in their 
entirety. 
In one embodiment, various ribozymes containing 
sequences that are complementary to endogenous messenger 40 
RNA encoded by Latexin gene or by Latexin isoforms 
having at least about 70%, 75%, 80%, 85%, 90%, 95%, 
96%, 97%, 98%, or 99% sequence similarity to SEQ ID NO: 
1 (i.e., a sense-strand of human Latexin cDNA), can be 
employed by persons skilled in the art in order to reduce 45 
Latexin expression and/or Latexin activity that results in the 
protection of HSCs from the damage caused by ionizing 
radiation and/or chemotherapy. Ribozymes, including the 
"hammer-head" ribozyme, are RNA molecules that bind 
target mRNA by assuming a unique secondary structure 50 
when hybridized to target mRNA, which enables catalytic 
hydrolysis of a phosphodiester bond within in the backbone 
of target mRNA. Efficient cleavage by a ribozyme requires 
the presence of divalent ions, such as magnesium, and is also 
dependent on target RNA structure, and relative proximity 55 
between ribozyme and target molecule. RNA localization 
signals or RNA chaperones may be used so that low con-
centrations of ribozymes are sufficiently effective in silenc-
ing Latexin and Latexin isoforms. Ribozymes can be chemi-
cally synthesized in vitro, and can be transcribed from 60 
expression vectors in vivo. Methods for ribozyme construc-
tion and utilization are known by persons skilled in the art. 
Doudna and Cech, Nature, 418:222-228 (2002); Kuwahara 
et al. J. Biochem., 132:149-155 (2002); Michienzi and 
Rossi, Methods Enzymol. 341:581-596 (2001); and Good et 65 
al. Gene Ther. 4:45-54, (1997) are herein incorporated by 
reference. 
January 18, page 33 (1993)); Chen et al. J. Amer. Chem. Soc. 
116:2661 (1994)), such as isoprenoids (U.S. Pat. No. 5,569, 
588), thiazolidinones and metathiazanones (U.S. Pat. No. 
5,549,974), pyrrolidines (U.S. Pat. Nos. 5,525,735 and 
5,519,134), morpholino compounds (U.S. Pat. No. 5,506, 
337), and benzodiazepines (U.S. Pat. No. 5,288,514), oli-
gocarbamates (Cho et al. Science 261:1303 (1993)), and 
peptidyl phosphonates (Campbell et al., J. Org. Chem. 
59:658 (1994)). Exemplary combinatorial libraries include: 
various peptide libraries (U.S. Pat. No. 5,010,175; Furka, 
Int. J. Pept. Prat. Res. 37:487-493 (1991); Houghton et al., 
Nature 354:84-88 (1991)); peptoid libraries (PCT Publica-
tion No. WO 91/19735); encoded peptides (PCT Publication 
No. WO 93/20242); random bio-oligomers (PCT Publica-
tion No. WO 92/00091); benzodiazepines (U.S. Pat. No. 
5,288,514); diversomers such as hydantoins, benzodiaz-
epines and dipeptides (Hobbs et al., Proc. Nat. Acad. Sci. 
USA90:6909-6913 (1993)); vinylogous polypeptides (Hagi-
hara et al., J. Amer. Chem. Soc. 114:6568 (1992)); nonpep-
tidal peptidomimetics with glucose scaffolding (Hirschmann 
et al. J. Amer. Chem. Soc. 114:9217-9218 (1992)); various 
nucleic-acid libraries; various peptide-nucleic acid libraries 
(U.S. Pat. No. 5,539,083); various carbohydrate libraries 
(Liang et al., Science, 274:1520-1522 (1996); U.S. Pat. No. 
5,593,853)); and various antibody libraries (Vaughn et al., 
Nature Biotechnology, 14(3):309-314 (1996)). 
Targeting Functionally-Related Isoforms of Latexin 
The present methods and compositions can be employed 
for targeting variants of Latexin that have similar properties/ 
activities within HSCs of many types of mammalian sub-
jects. Functionally-related isoforms of Latexin can be iden-
tified by searching various genomic databases and 
conducting multi-genome-wide sequence alignments in 
order to identify homologous sequences of interest. Related 
orthologous sequences can be identified by searching com-
posite genomic databases. The breath of a database search is 
limited by the scope of representative model organisms for 
which sequence data is available. 
Homology can be determined by various routine methods, 
including alignments of open-reading-frames ("ORF s") con-
tained in private and/or public databases. Any suitable 
mathematical algorithm may be used to determine percent 
identities and percent similarities between any two 
sequences being compared. For example, nucleic acid and 
11 
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TABLE 1 protein sequences of the present invention can be used as a 
"query sequence" to perform a search against sequences 
deposited within various public databases to identity other 
family members or evolutionarily-related sequences. 
Genomic sequences for various organisms are currently 5 
available, including fungi, such as the budding yeast, or 
Saccharomyces cerevisiae; invertebrates, such as Cae-
norhabditis elegans and Drosophila melangaster; and mam-
mals, such as the mouse, rat, and human. Exemplary data-
bases for identifying orthologs of interest include Genebank, 
Swiss Protein, EMBL, and National Center for Biotechnol-
ogy Information ("NCBI"), and many others known in the 
art. These databases enable a user to set various parameters 
for a hypothetical search according to the user's preference, 
Gene Bank Accession Number for Exemplary Mouse, Hwnan, and Rat 
Latexin mRNA. 
Organism Accession Nwnber Gene IDS 
Mus musulus (Mouse) NM-016753 31980631 
Rattus norvegicus (Rat) NM-031655 14269567 
10 Homo Sapiens (Human) NM-020169 21359932 
or to utilize default settings. Tables 1-3, provided below, list 
the accession numbers and gene identification numbers for 15 
exemplary manmialian orthologs. Suitable Latexin variants 
that may be targeted for suppression or inhibition includes 
e.g, the variants of SEQ ID NO: 1 or SEQ ID NO: 2 
described herein. In another embodiment, suitable Latexin 
variants that may be targeted for suppression or inhibition 20 
include variants of SEQ ID NO: 1 or SEQ ID NO: 2 other 
than the carboxypeptidase inhibitor (CARIN) described in 
U.S. Pat. No. 5,998,373. 
TABLE 2 
Gene Bank Accession Number for Exemplary Mouse, Hwnan, and Rat 
Latexin Protein. 
Organism 
Mus musulus (Mouse) 
Rattus norvegicus (Rat) 














Gene IDS Identity Gene Information 
Mus AK032170.1 26327996 99.91 Mus musulus adult male olfactory 
musulus brain cDNA, RIKEN full-length 
(Mouse) enriched library, clone: 6430407E02 
product: Latexin, full insert sequence 
Mus AK149981.1 74211713 100.00 Mus musulus bone marrow 
musulus macrophage cDNA, RIKEN full-
(Mouse) length enriched library, 
clone: G530111019 
product: Latexin, full insert sequence 
Mus D88769.1 1669620 99.50 Mus musulus mRNA for Latexin, 
musulus complete eds 
(Mouse) 
Mus AC124190.4 23499687 100.00 Mus musulus BAC clone RP23-
musulus 267M9 from 3, complete sequence 
(Mouse) 
Mus AC124190.4 23499687 100.00 
musulus 
(Mouse) 
Mus AC124190.4 23499687 100.00 
musulus 
(Mouse) 
Mus AC124190.4 23499687 100.00 
musulus 
(Mouse) 
Mus AC124190.4 23499687 100.00 
musulus 
(Mouse) 
Mus AC124190.4 23499687 100.00 
musulus 
(Mouse) 
Mus AK018305.1 12857946 99.58 Mus musulus 10 days neonate 
musulus cerebellum cDNA, RIKEN full-length 
(Mouse) enriched library, clone: 6530401Al0 
product: Latexin, full insert sequence 
Mus AK198791.1 56022968 100.00 Mus musulus cDNA, 
musulus clone: Y1G0129D08, strand: minus, 
(Mouse) reference: ENSEMBL: Mouse-
Transcript-
ENST: ENSMUST00000058981, 
based on BLAT search 






Mammalian Homologs for Latexin. 
Percentage 
Gene IDS Identity Gene Information 
56011207 99.52 Mus musulus cDNA, 
musulus clone: YOG0139J09, strand: minus, 
(Mouse) reference: ENSEMBL: 
Mouse-Transcript-
ENST: ENSMUST00000058981, 
based on BLAT search 
Rattus Y18435.2 6066618 94.33 Rattus norvegicus Latexin gene, exons 
norvegicus 1 to 6 
(Rat) 
Rattus Y18435.2 6066618 96.92 
norvegicus 
(Rat) 
Assays adhesive properties of hematopoietic cells and studies the 
Various assays measure the number and functionality of 
HSCs and their progeny. These assays include in vitro 
phenotyping assays, in vitro clonogenic assays, and in vivo 
transplantation assays. 
20 interaction between hematopoietic cells and stromal cells. 
Flow cytometry reveals important information on the 
phenotypes of different hematopoietic cell subsets. Combin- 25 
ing fluorescently labeled antibodies against cell surface 
receptors with flow cytometric analysis allows for the iden-
tification and isolation of progenitor and stem cells. Gener-
ally, there is a good correlation between the phenotype and 
in vivo reconstitution potential of HSCs; under stress con- 30 
ditions (aging, chemo/radio therapy or transplantation), phe-
notypic isolation strategies vary in their efficiency in select-
ing HSCs. 
The colony-forming unit (CFU) assay is an in vitro assay 
widely used to detect and quantify hematopoietic progenitor 35 
cells. In this assay, BM, spleen or peripheral blood cells are 
mixed with methylcellulose-based medium supplied with a 
combination of cytokines, and cultured for one or two 
weeks. Progenitor cells of different lineages form colonies 
which have distinct morphologies. In this assay, each colony 40 
is counted and characterized by lineage according to their 
morphologies. Thus, it offers insight into the lineage speci-
ficity of cells, rather than assessing the functional activity of 
primitive, pluripotent HSCs. 
The cobblestone-area forming cell (CAFC) assay is an in 45 
vitro limiting-dilution assay used to determine the frequency 
of hematopoietic cell subsets in a developmental hierarchy. 
A stromal cell layer (e.g. FBMD-1 cells) is pre-seeded and 
cultured in 96-well plates, and allows for in vitro long-term 
culturing of stem and progenitor cell. After the stromal cells 50 
reach confluency, bone marrow cells are plated on top of 
them. The primitive HPCs (hematopoietic progenitor cells) 
and HSCs will form the colony underneath the stromal cell 
layer. The colonies are monitored and counted under the 
microscope weekly for 5 weeks. The later the cells are in 55 
forming the colony, the more primitive the cells are. That is, 
cells forming colonies at early time-points (day 7, 14 and 21) 
are different stages of HPCs, and those forming colonies at 
day 28 and 35 are HSCs. CAFC day 35 cells are commonly 
used to determine primitive HSCs. CAFC assay can be used 60 
to determine the adhension capacity of HSCs to stromal 
cells. In this assay, hematopoietic cells are plated onto a 
stromal layer and the hematopoietic cells and stromal cells 
are allowed to interact for 2-4 hours. The non-adherent cells 
are then washed away, leaving the adherent cells in culture. 65 
These adherent cells will form cobblestone-areas at later 
time points. The adhesion assay generally measures the 
The CAFC assay is a reliable approach for measuring the 
frequency and clonogenic function of hematopoietic pro-
genitor and stem cells. 
EXAMPLES 
Animals 
Young C57BL/6 (B6) mice (8-16 weeks) were purchased 
from The Jackson Laboratories (Bar Harbor, Me.). Latexin 
constitutive knockout mice were generated by Taconic/ 
Artemis (Germantown, N.Y.) and used at a young age (8-16 
weeks). Male animals were used in this study. All animals 
were housed in the animal facilities of the University of 
Kentucky under pathogen-free conditions according to NIH-
mandated guidelines for animal welfare and were given food 
and water ad libitum. Lxn constitutive knock-out mice were 
used as a model and they were treated with ionizing radia-
tion. The Lxn deficient mouse model was generated by 
Taconic/armetis under contract let by the inventors. The 
salient alteration was a deletion of Lxn exons 2-4 resulting 
in a complete knockout of LXN synthesis. 
Ionizing Radiation 
The mice and cells were exposed to various doses of 
radiation (6.5 Gy, 8 Gy, 9 Gy and split doses of 12 Gy) in 
a 13 7 Cs ganima irradiatior (J. L. Shepherd and Associates, 
Glendale, Ga.) at a dose rate of 153 rad/min. 
Peripheral Blood Cell Counts 
Animals were anesthetized with isoflurane (Butler Animal 
Health Supply, Dublin, Ohio). Peripheral blood was col-
lected from retro-orbital venous plexus into EDTA-coated 
microtainer tubes (Becton, Dickinson and Company, Frank-
lin Lakes, N.J.). Circulating leukocytes, erythrocytes and 
platelets were counted by analyzing 20 µL of blood using a 
Hemavet 950 (Drew Scientific, Dallas, Tex.). 
Hematopoietic Cell Identification and Isolation 
Bone marrow cells were flushed from the femora and 
tibiae using a 1 ml syringe and 22G needle into Hanks 
balanced salt solution (HBSS) with 2% fetal bovine serum 
(FBS) (Gibco, Grand Island, N.Y.). Progenitor cells were 
discriminated from stem cells by the lack of cell surface 
antigens characteristic of cells committed to individual 
lineages. Antibodies against these antigens included CDS 
and CD8a, B220, Mac-1, Gr-1, and Ter119 were bioti-
nylated. Strepavidin secondary antibody was used to detect 
lineage negative cells. To further purify primitive stem cells, 
the stem cell markers Sca-1 and c-Kit were incorporated into 
the staining procedure. Dead cells were excluded by pro-
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pidium iodide (PI) that stains exposed double-strand DNA. 
All monoclonal antibodies were purchased from eBiosci-
ence (San Diego, Calif.), Biolegend (San Diego, Calif.), or 
BD Pharmingen (San Jose, Calif.). 
Cell Analysis and Sorting 
Bone marrow cells were analyzed and sorted on a BD 
FacsAria II flow cytometer (Becton Dickinson, Franklin 
Lakes, N.J.). Cells were sorted into phosphate buffered 
saline (PBS) with 0.5% FBS for further use. Flow cytometry 
data was analyzed using FlowJo software (Tree star, Ash-
land, Oreg.). 
Apoptosis Analysis 
Bone marrow cells were prepared and stained as 
described above. The fluorochrome-conjugated apoptotic 
marker Annexin V along with Propidium Iodide (PI) (both 
from BD Pharmingen) were used to identify apoptotic cells 
(PI-/Annexin V+). Stained cells from Lxn-/- animals and 
B6 animals were analyzed by flow cytometer. 
Colony Forming Cell (CFC) Assay 
Methylcellulose-based culture media (MethoCult) was 
purchased from Stem Cell Technologies, Vancouver, Canada 
and contained the following cytokines: stem cell factor 
(SCF), IL-3 and IL-6. For this assay, 5xl04 whole BM cells 
in 100 µL HBSS were thoroughly admixed with 1 mL 
complete MethoCult media, plated into petri-dishes, and 
incubated at 37° C. Individual wells of duplicates were 
counted on day 10 to quantify lineage specific colonies. 
Example 1 
Lxn Function in Response to Hematopoietic 
Stress-induced Apoptosis 
16 
was significant greater than B6 mice before irradiation and 
3 days after exposure to irradiation (FIG. 2A). LSK cell 
counts dropped dramatically at day 7 in both experiment 
groups. However, the HSC recovery rate was accelerated in 
5 Lxn-/- mice. 
The number ofLSK cells compartment increased approxi-
mately 6-fold at day 14 and 3-fold at day 21 in Lxn-/- mice 
(FIGS. 2A and B). The numbers ofLK (Lin-/c-Kit+/Sca-1-) 
and LS (Lin-/c-Kit-/Sca-1 +) cells were also increased at 
10 
day 14, though not to the same extent of LSK cells. These 
data indicate that deletion ofLxn selectively protects primi-
tive cells more so than differentiated cells (FIG. 2B). 
In flow cytometric analysis, phenotypic markers were 
used to quantify HSPC numbers. To further identify the 
numbers of functional HSPCs, CFU assays were performed 
15 with 5xl04 whole BM cells from 6.5 Gy sub-lethally irra-
diated animals. The pattern of HSPC recovery in Lxn-/-
mice is similar to that pattern observed when using pheno-
typic markers. 
Lxn-/- whole BM cells from mice at day 0, 1, 3, 14 and 
20 28 post irradiation formed significantly more colonies, 
which indicated an accelerated recovery rate compared to 
B6 cells (FIG. 2C). This observation supported previous 
LSK cell population frequency results. 
A similar trend in BM cell recovery was also observed. 
25 The numbers of surviving whole BM cells were significantly 
diminished (24-28 million cells per femur to less than 3 
million cells per femur) shortly after irradiation (day 3), and 
subsequently stable returned back to normal levels by day 28 
in Lxn-/- mice (FIG. 2D). Lxn-/- BM cells showed an 
30 
accelerated recovery rate over B6 BM cells at day 7, 14 and 
28 (FIG. 2D), in accordance with increased tempo in recov-
ery of HSPCs (FIG. 2A). 
Example 3 
Hematologic and Immune Recovery 
Because radiation-induced hematological failure and 
immune failure are the primary causes of low survival after 
high dose radiation exposure, hematologic and immune 
recovery in a time dependent manner following radiation 
exposure were examined. 
The effects of loss of Lxn in BM cell radiation resistance 
were studied first. Total body irradiation (TBI) was admin- 35 
istered to Lxn-/- mice and to B6 control mice. Various 
dosages of gamma radiation including lethal doses of 8 Gy 
and 9 Gy were tested, as well as clinically relevant split 
doses totaling 12 Gy. The survival rate for each treatment 
was then tested. All of the lethally irradiated B6 animals died 40 
within 20 days after receiving a single 8 or 9 Gy dose (FIG. 
lA). Surprisingly, the survival rate of Lxn-/- mice was 
significantly greater. As shown in FIG. lA, 60% of the 
Lxn-/- mice survived the 8 Gy dose of irradiation and 20% 
Wild type B6 and Lxn-/- animals were exposed to a 
sub-lethal (6.5 Gy) dose of radiation to trigger reversible 
hematopoietic injury, and the rate ofrecovery of blood cells 
45 was monitored. of Lxn-/- mice survived the 9 Gy dose. 
To further characterize the radio-protective effect and 
study its implication in medical treatment, two experimental 
groups were irradiated with 12 Gy TBI using a fractionated 
schedule of2 Gy every 12 hours. 80% ofLxn-/- mice ( 4 out 
5) survived over 600 days whereas only 20% of WT control 50 
mice (1 out 5) survived. The difference is significant 
(p<0.05). (FIG. 18) 
Example 2 
As demonstrated in FIG. 3A, loss of Lxn significantly 
accelerated the recovery of total leukocytes in blood. 
Untreated Lxn-/- mice have -30% more leukocytes than 
their wild type counterparts (FIG. 3A). 
Leukocytes in both strains dropped to approximately 
1,000 cells/µL in peripheral blood one day after irradiation. 
The number of Lxn-/- leukocytes rapidly recovered at day 
7 and remained significantly greater than B6 ( approximately 
100% more) up to day 14. The counts of neutrophils (FIG. 
HSC and HPC Recovery after Radiation Exposure 
55 3B) and lymphocytes (FIGS. 3B and 3C) had similar recov-
ery patterns as the total leukocytes. Lxn-/- mice showed a 
faster recovery over the period from day 7 to 28 compared 
to B6 animals. A single dose of 6.5 Gy TBI (sub-lethal dose) was 
administered to both experimental groups (Lxn-/- mice and 
wild-type B6 mice). The recovery ofHSPC post irradiation 60 
was determined by both flow cytometer (which counts 
phenotypic HSPC) and in vitro colony-forming unit (CFU) 
assay (which measures functional HSPC) in a time depen-
dent manner. At each time point, BM cells were harvested, 
BM cellularity was analyzed, and the size of the surviving 65 
LSK cell population in both groups was measured. The 
number ofphenotypic HSPCs (LSK cells) in Lxn-/- mice 
The level of neutrophil counts in both groups overshot 
normal levels, whereas lymphocytes never fully recovered. 
Platelet (FIG. 3D) counts in both groups recovered to normal 
by day 28. The number ofLxn-/- platelets was significantly 
greater than B6 platelets 3-7 after irradiation. 
Collectively, a significant recovery advantage was 
observed at multiple time points in both hematologic and 
immune systems in PB, possibly resulting from accelerated 
recovery in HSPCs in BM. 
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The lineage distribution of mature blood cells between 
granulocyte, monocyte, T-cell and B-cell lymphocytes using 
various lineage markers were also studied. The gamma 
irradiation caused immediate lympho- and myelo-ablation at 
day 1 and an altered lineage distribution that favored the 
myeloid lineage (FIG. 3E). The lymphoid lineage started to 
gradually recover 3 days after radiation. 
5 
was significantly lower in Lxn-/- mice after 6.5 Gy sub-
lethal irradiation (FIG. 4A). During homeostasis, apoptotic 
cell frequency is inherently significantly lower in Lxn-/-
LSK cells (day O in FIG. 4A). This low apoptotic frequency 
was sustained from day 7 to day 28 after irradiation. On day 
14 the percentage of apoptotic LSK cells was 5-fold lower 
in Lxn-/- mice compared to B6 mice (FIGS. 4A, 4B and 
4C). Notably, the percentage of apoptotic cells in Lin-, LK 
and LS subpopulations diminished along with Lxn ablation 
on day 14, but did not reach statistical significance (FIG. 
The distribution ofB lymphocytes in Lxn-/- mice recov-
ered to near normal (50%), but B6 B lymphocytes never 
fully recovered (30%) (FIG. 3E). 
10 
In sum, the recoveries of total leukocyte, platelet, granu-
locyte and lymphocyte subsets were significantly acceler-
ated in Lxn-/- mice following ionizing radiation. Further, 
Lxn-/- cells favor B cell lineage production in long-term 
reconstitution. 
4C). The apoptotic frequency was significantly reduced only 




the apoptotic rate in primitive BM cells. 
Apoptotic frequency was directly examined using 
Annexin V staining. The percentage of apoptotic LSK cells 
It will be appreciated that, although specific embodiments 
of the invention have been described herein for purposes of 
illustration, various modifications may be made without 
departing from the spirit and the scope of the invention. 
Accordingly, the invention is not limited except as by the 
appended claims. 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 2 
<210> SEQ ID NO 1 
<211> LENGTH, 1113 
<212> TYPE, DNA 
<213> ORGANISM, human 
<400> SEQUENCE, 1 
agaageagte ageeeaggge teteggatge agggageetg ggcccaaaca geagetteeg 60 
gagteggaag gagetgagga agaagacaga etgaaggage ttgegaettt teegeetegg 120 
caaccggacc cagcagcaag eaggaeggge ggegetetge taetggteee gttaageeag 180 
agtagcccaa geeetgaagt cactgctcat eeggaatgga aatcccgccg accaactacc 240 
cagcctccag ggeggeettg gtggeaeaga actacatcaa ctaccagcag gggaeeeege 300 
aeagggtgtt tgaggtgeag aaggtcaaac aagccagcat ggaggatatt eeaggaagag 360 
gacataagta tcgccttaaa tttgetgttg aagaaattat acaaaaacaa gttaaggtga 420 
actgcacagc tgaagtaett tacccttcaa egggaeaaga aactgcacca gaagtcaact 480 
tcacatttga aggagaaaet ggaaagaate eagatgaaga agacaacaca ttttatcaaa 540 
gaettaagte eatgaaggaa eegetagaag cacaaaatat tccagacaat tttggaaatg 600 
tatctccaga aatgacgctc gttetaeatt tageetgggt tgeetgtggt tatataatat 660 
ggcaaaattc tactgaagac aeatggtata aaatggtaaa aattcaaact gteaageaag 720 
tgcaaagaaa tgatgaettt attgaattag actacaccat tctacttcat aatatagcat 780 
eteaggagat tatteeetgg caaatgcaag ttetetggea tccacaatac ggeaetaaag 840 
taaaacataa tageegtetg ccaaaggaag tacaactgga ataaacaaaa accctaacac 900 
tggaagtgta aacatgtcta ttgatgtgta tgccaatttc aetggeatet agettatgag 960 
gccaaataat cccaaagtgt cactttatat aaatgtettg attacagtat agaactttat 1020 
agagtccata atacaaagta tcactacata aaaatgtctt taaaacagta atagtggtat 1080 
gtatatccaa aataaaaagc ttcaatttca gee 1113 
<210> SEQ ID NO 2 
<211> LENGTH, 222 
<212> TYPE, PRT 
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-continued 
<213> ORGANISM, human 
<400> SEQUENCE, 2 
Met Glu Ile Pro Pro Thr Asn Tyr Pro Ala Ser Arg Ala Ala Leu Val 
1 5 10 15 
Ala Gln Asn Tyr Ile Asn Tyr Gln Gln Gly Thr Pro His Arg Val Phe 
20 25 30 
Glu Val Gln Lys Val Lys Gln Ala Ser Met Glu Asp Ile Pro Gly Arg 
35 40 45 
Gly His Lys Tyr Arg Leu Lys Phe Ala Val Glu Glu Ile Ile Gln Lys 
50 55 60 
Gln Val Lys Val Asn Cys Thr Ala Glu Val Leu Tyr Pro Ser Thr Gly 
65 70 75 80 
Gln Glu Thr Ala Pro Glu Val Asn Phe Thr Phe Glu Gly Glu Thr Gly 
85 90 95 
Lys Asn Pro Asp Glu Glu Asp Asn Thr Phe Tyr Gln Arg Leu Lys Ser 
100 105 110 
Met Lys Glu Pro Leu Glu Ala Gln Asn Ile Pro Asp Asn Phe Gly Asn 
115 120 125 
Val Ser Pro Glu Met Thr Leu Val Leu His Leu Ala Trp Val Ala Cys 
130 135 140 
Gly Tyr Ile Ile Trp Gln Asn Ser Thr Glu Asp Thr Trp Tyr Lys Met 
145 150 155 160 
Val Lys Ile Gln Thr Val Lys Gln Val Gln Arg Asn Asp Asp 
165 170 
Glu Leu Asp Tyr Thr Ile Leu Leu His Asn Ile Ala Ser Gln 
180 185 190 
Ile Pro Trp Gln Met Gln Val Leu Trp His Pro Gln Tyr Gly 
195 200 205 
Val Lys His Asn Ser Arg Leu Pro Lys Glu Val Gln Leu Glu 
210 215 220 
The invention claimed is: 
1. A method for protecting against hematopoietic stem 
cell (HSC) damage caused by chemotherapy and/or radia-
tion, the method comprising: 
40 
administering to a subject in need thereof a pharmaceu- 45 
tical composition comprising an siRNA that reduces 
expression and/or activity of latexin, 
wherein latexin is a latexin polynucleotide variant that 
binds to the siRNA, 
wherein the latexin polynucleotide variant has at least 50 
95% sequence identity to SEQ ID NO: 1, and 
wherein the latexin polynucleotide encodes a latexin 
polypeptide variant that has at least 95% sequence 
identity to SEQ ID NO: 2, and 
wherein the subject in need thereof has a solid tumor and 55 
is scheduled to start chemotherapy and/or radiation 
therapy. 
2. The method of claim 1, wherein the pharmaceutical 
composition increases overall survival of the subject. 
3. The method of claim 1, wherein the pharmaceutical 60 





7. A method for protecting against hematopoietic stem 
cell (HSC) damage caused by chemotherapy and/or radia-
tion, the method comprising: 
administering to a subject in need thereof a pharmaceu-
tical composition comprising an siRNA that reduces 
expression and/or activity of latexin, 
wherein latexin is a latexin polynucleotide variant that 
binds to the siRNA, 
wherein the latexin polynucleotide variant has at least 
95% sequence identity to SEQ ID NO: 1, and 
wherein the latexin polynucleotide encodes a latexin 
polypeptide variant that has at least 95% sequence 
identity to SEQ ID NO: 2, and 
wherein the subject in need thereof has a solid tumor and 
is already receiving chemotherapy and/or radiation 
therapy. 
8. The method of claim 7, wherein the pharmaceutical 
composition increases overall survival of the subject. 
9. The method of claim 7, wherein the pharmaceutical 
composition protects the HSCs from DNA damage. 
4. The method of claim 1, wherein the pharmaceutical 
composition decreases the frequency of HSC apoptosis. 
5. The method of claim 1, wherein the pharmaceutical 
composition promotes HSC proliferation by at least 25%. 
6. The method of claim 1, wherein the damage is caused 
to the bone marrow. 
10. The method of claim 7, wherein the pharmaceutical 
composition decreases the frequency of HSC apoptosis. 
11. The method of claim 7, wherein the pharmaceutical 
65 composition promotes HSC proliferation by at least 25%. 
12. The method of claim 7, wherein the damage is caused 
to the bone marrow. 
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1_3. The metho_d _of claim 1, A method for protecting 
agamst hematopmetJc stem cell (HSC) damage caused by 
chemo~h~rap~ and/or radiation, the method comprising: 
adm1mstenng to a subject in need thereof a pharmaceu-
tical composition comprising an siRNA that reduces 5 
expression and/or activity of latexin, 
wherein latexin is a latexin polynucleotide variant that 
binds to the siRNA, 
wherein the latexin polynucleotide variant has at least 
95% sequence identity to SEQ ID NO: 1, and 10 
wherein the latexin polynucleotide encodes a latexin 
polypeptide variant that has at least 95% sequence 
identity to SEQ ID NO: 2, and 
wherein the subject in need thereof is selected from the 
group consisting of a subject receiving chemotherapy 15 
and/or radiation therapy and a subject scheduled to start 
chemotherapy and/or radiation therapy, and 
wherein the subject in need thereof has normal levels of 
latexin expression in his or her bone marrow. 
14. The method of claim 13, wherein the pharmaceutical 20 
composition increases overall survival of the subject. 
22 
administering to a patient in need thereof a pharmaceu-
tical composition comprising an siRNA that reduces 
expression and/or activity of latexin, 
wherein latexin is a latexin polynucleotide variant that 
binds to the siRNA, 
wherein the latexin polynucleotide variant has at least 
95% sequence identity to SEQ ID NO: 1, and 
wherein the latexin polynucleotide encodes a latexin 
polypeptide variant that has at least 95% sequence 
identity to SEQ ID NO: 2, and 
wherein the subject in need thereof is selected from the 
group consisting of a subject receiving chemotherapy 
and/or radiation therapy and a subject scheduled to start 
chemotherapy and/or radiation therapy, and 
wherein the subject in need thereof has a solid tumor and 
wherein the bone marrow damage is caused by che-
motherapy and/or radiation therapy. 
19. The method of claim 18, wherein the pharmaceutical 
composition decreases apoptotic frequency ofhematopoietic 
stem cells (HSCs ). 
20. The method of claim 18, wherein the pharmaceutical 
composition promotes HSC proliferation. 
15. The method of claim 13, wherein the pharmaceutical 
composition protects the HSCs from DNA damage. 
16. The method of claim 13, wherein the pharmaceutical 
composition decreases the frequency of HSC apoptosis. 
17. The method of claim 13, wherein the pharmaceutical 
composition promotes HSC proliferation by at least 25%. 
18. A method for treating bone marrow damage, the 
method comprising: 
21. The method of claim 20, wherein the pharmaceutical 
25 
composition promotes HSC proliferation by at least 25%. 
22. The method of claim 18, wherein the subject in need 
thereof is already receiving chemotherapy and/or radiation 
therapy. 
* * * * * 
